Cargando…
Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients
BACKGROUND: Management of elderly inflammatory bowel disease (IBD) patients (≥ 65 years of age) is complicated due to many factors, including a higher risk of cancer, which may impact therapeutic decisions. OBJECTIVE: The aim of this study was to determine the risk of cancer among elderly IBD patien...
Autores principales: | Khan, Nabeel, Vallarino, Carlos, Lissoos, Trevor, Darr, Umar, Luo, Michelle |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5705754/ https://www.ncbi.nlm.nih.gov/pubmed/29170864 http://dx.doi.org/10.1007/s40266-017-0498-y |
Ejemplares similares
-
Development and Validation of an Inflammatory Bowel Disease Severity Index Using US Administrative Claims Data: A Retrospective Cohort Study
por: Chen, Grace, et al.
Publicado: (2020) -
Risk factors for postoperative infection after gastrointestinal surgery among adult patients with inflammatory bowel disease: Findings from a large observational US cohort study
por: Liang, Huifang, et al.
Publicado: (2018) -
Adverse Events Related to SARS-CoV-2 Vaccine in a Nationwide Cohort of Patients With Inflammatory Bowel Disease
por: Mahmud, Nadim, et al.
Publicado: (2022) -
Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases
por: Moran, Kellyn, et al.
Publicado: (2019) -
Response to “Comment on Retrospective Claims Analysis Indirectly Comparing Medication Adherence and Persistence Between Intravenous Biologics and Oral Small-Molecule Therapies in Inflammatory Bowel Diseases”
por: Moran, Kellyn, et al.
Publicado: (2020)